Home » Stocks » INBX

Inhibrx, Inc. (INBX)

Stock Price: $16.82 USD 0.71 (4.41%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 594.76M
Revenue (ttm) 12.89M
Net Income (ttm) -76.12M
Shares Out 25.26M
EPS (ttm) -3.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $16.82
Previous Close $16.11
Change ($) 0.71
Change (%) 4.41%
Day's Open 16.33
Day's Range 15.30 - 16.98
Day's Volume 79,765
52-Week Range 14.27 - 50.97

News

Hide News

Inhibrx Inc (NASDAQ: INBX) has announced results from the dose escalation of the Phase 1 study evaluating INBRX-105 in locally advanced or metastatic solid tumors. INBRX-105 is a precisely engineered mu...

2 months ago - Benzinga

SAN DIEGO, March 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fi...

2 months ago - PRNewsWire

SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced to...

3 months ago - PRNewsWire

About INBX

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates als... [Read more...]

Industry
Biotechnology
IPO Date
Aug 19, 2020
Stock Exchange
NASDAQ
Ticker Symbol
INBX
Full Company Profile

Financial Performance

In 2020, Inhibrx's revenue was $12.89 million, a decrease of -2.44% compared to the previous year's $13.21 million. Losses were -$76.12 million, 48.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Inhibrx stock is "Strong Buy." The 12-month stock price forecast is 40.50, which is an increase of 140.78% from the latest price.

Price Target
$40.50
(140.78% upside)
Analyst Consensus: Strong Buy